Purpose This study was designed to examine the aggressive features of BRAF-positive
papillary thyroid cancer (PTC) and association with age. Methods We compared the …

The impact of BRAF mutations on the clinical outcomes of PTC remains debatable. In ATCs,
in turn, BRAF mutations identify patients eligible for targeted therapy, which is now …

BACKGROUND: To date, a mutation of the BRAF oncogene is the most common genetic
alteration found in papillary thyroid carcinoma (PTC) and is associated with extrathyroidal …

Objective: To examine the prevalence of BRAF mutation among thyroid cancer histologic
subtypes and determine the association of BRAF mutation with indicators of poor prognosis …

Introduction The use of molecular markers, especially BRAF and TERT promoter mutations,
for risk stratification in papillary thyroid carcinoma (PTC) is subject to continuing debate. In …

Background: The mutated BRAF V600E protein has been specifically detected in papillary
thyroid carcinomas (PTCs) using immunohistochemical (IHC) analysis. The clonal origin of …

Purpose This study investigated the utility of BRAF mutation testing of thyroid fine-needle
aspiration biopsy (FNAB) specimens for preoperative risk stratification in papillary thyroid …

Summary Background The activating BRAFV600E mutation is the most common genetic
alteration reported in papillary thyroid carcinoma (PTC). While some reports suggest the …

Papillary thyroid carcinoma (PTC), the most common malignancy of the endocrine system, is
frequently driven by BRAF V600E mutation, which was reported in 35–60% cases in …

Background: The BRAF V600E mutation, the most frequent genetic alteration in papillary
thyroid carcinoma (PTC), was demonstrated to be a poor prognostic factor. The aim of this …